Ph 1b Safety/Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines With Monovalent or Bivalent Dosing

Condition:   Norovirus Infection Interventions:   Biological: VXA-G1.1-NN;   Biological: VXA-G2.4-NS;   Biological: Placebo Tablets Sponsor:   Vaxart Recruiting

Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials